Pharmaceutical Technology-12-02-2007

Pharmaceutical Technology

In the Field

December 02, 2007

News

31

12

Congress Focuses on FDA Inspections of Foreign Drug Facilities; Medical Students Oppose Big Pharma's Influence on Campus; FDA Revises Postmarketing Reporting Requirements

What's Next in: Strategy and Regulation

December 02, 2007

Special Report

31

12

There are at least two major factors that will shape the manufacturing industry as a whole. Daniel Ruppar, Industry Manager (North America) for the Pharmaceuticals and Biotechnology Division of Frost & Sullivan predicts that, due to continued globalization, we can expect to see "growth centers for the industry move to emerging market sectors."

Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation

December 02, 2007

Peer-Reviewed Research

31

12

Various manufacturing techniques can improve a drug's solubility, thus increasing its bioavailability. The authors examined whether melt granulation can enhance drug solubility using meloxicam as the drug substance and myrj-52 as the binder.

What's Next In: Outsourcing

December 02, 2007

Special Report

31

12

Contract service providers exist to help clients meet their strategic and financial business objectives. So any prognostication on what the pharmaceutical outsourcing industry will look like in 30 years is really a forecast of the nature and speed of changes in pharmaceutical technologies and business models.

What's Next In: Ingredients

December 02, 2007

Special Report

31

12

Catalysis plays a critical role in the synthesis of active pharmaceutical ingredients (APIs). It provides a way to improve yield, achieve desired stereoselectivity, improve reaction conditions, and synthesize increasingly complex APIs. Recent advances in catalyzed-olefin metathesis reveal its value and promise in the pharmaceutical industry.

Pharma Predictions

December 02, 2007

Viewpoint

31

12

In honor of Pharmaceutical Technology's 30th anniversary, the editors conducted a survey of 320 readers last spring to discuss industry advances and future directions. Here are some of your foward-looking responses.

What's Next In: Solid-Dosage Formulation

December 02, 2007

Special Report

31

12

Individualized dosing for specific patient needs has been the goal of medical and pharmacotherapy specialists since they first envisioned pharmacogenetic evaluation. With the measurement of individual levels of metabolism, the optimum dose can be calculated for each individual patient.

Go Green This New Year

December 02, 2007

This Time Around

31

12

As we get ready to head into the new year, chief executive and financial officers may be making their wish lists for 2008. Grow revenue. Increase pipeline. Establish new facility abroad. Acquire small-sized generics company. And so forth. But why not add something "green" to the list?Why not consider ways to help the environment while aiming for success?

What's Next In: Analytical Testing

December 02, 2007

Special Report

31

12

Industry and regulatory organizations agree that the current focus on product quality will play a major role in shaping pharmaceutical development in the future. Key to this assessment of quality are the methods and technologies in pharmaceutical analytical testing.

The Disintegration and Dissolution of Nabumetone Dispersible Tablets

December 02, 2007

Peer-Reviewed Research

31

12

The authors analyzed the effects of complexation as well as the levels of ammonium bicarbonate and crospovidone on tablet wetting time (WT), disintegration time (DT), and percent dissolution efficiency at 60 min (%DE60).

What's Next In: Packaging

December 02, 2007

Special Report

31

12

Although the highly regulated pharmaceutical industry tends to be more like the tortoise than the hare when it comes to adopting new ideas, pharmaceutical packaging will be dramatically different 30 years from now in 2037.